Danilo Maddalo
Has grant
Group Leader
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Close
PostDoc Scholarship
Open Date: 2014-09-01
Close Date: 2015-09-01
Grant: Close
PostDoc Fellowship
Open Date: 2013-09-01
Close Date: 2014-09-01
Grant: Close
Travel Grant
Open Date: 2011-11-01
Close Date:
Grant: Close
Young Investigator Group Leader
Open Date: 2010-07-01
Close Date: 2014-07-01
Grant: Close
PhD fellowship
Open Date: 2006-09-01
Close Date: 2009-09-01
Articles (18)
Purpose: PIK3CA mutations frequently drive solid tumors, particularly hormone receptor–positive breast cancer. Inavolisib, an ATP-competitive p110α inhibitor, also promotes the degradation of mutated p110α. PI3K inhibitors have generally shown modest single-agent activity and have safety concerns. Patients and Methods: A first-in-human phase 1 study (NCT03006172) evaluated oral inavolisib in patients with PIK3CA -mutated solid tumors to determine the maximum tolerated dose and safety. Correlative analyses included ctDNA. Preclinical studies in cell lines and xenografts elucidated the role of FGFR2. Results: The maximum tolerated dose was 9 mg daily, with a manageable safety profile (e.g., hyperglycemia and diarrhea). Inavolisib showed linear pharmacokinetics, consistent pharmacodynamic modulation, and antitumor activity in hormone receptor–positive PIK3CA -mutated breast cancer (26% objective response rate and 45% clinical benefit rate). FGFR2 hotspot mutations in ctDNA were strongly associated with clinical benefit. Preclinically, oncogenic FGFR2 signaling enhanced inavolisib sensitivity by engaging HER3, RAS, and p85β, that facilitated mutated p110α degradation, surpassing nondegrading inhibitors. Combination therapy with FGFR2 inhibitors showed synergy and delayed resistance. Conclusions: These findings highlight a novel cooperativity between FGFR2 and p110α that boosts the effectiveness of inavolisib. The data support advancing precision oncology beyond single biomarkers to complex algorithms utilizing co-occurring alterations, suggesting that combining inavolisib with FGFR2 inhibitors may offer enhanced and more durable responses in PIK3CA/FGFR2 -altered tumors.
Year:
2026
Year:
2025
Year:
2025
RIT1 is a RAS-family GTPase that is mutated in 2.4% and amplified in up to 14% of lung adenocarcinoma patients. Yet, the oncogenic potential of RIT1 in the lungs is not completely understood. Many patients with RIT1 alterations are considered ‘oncogene-negative’, hence they are not eligible for any targeted therapy in the clinic. The role of RIT1 in cancer has been historically understudied due to the lack of in vitro and in vivo models harboring RIT1 alterations. In this study, we generated the first murine model of RIT1M90I-mutant lung cancer. We found that RIT1M90I was tumorigenic in the lungs and the tumors displayed histopathological features similar to lung adenocarcinoma. We leveraged this new model to assess both ex vivo and in vivo sensitivity of RIT1 tumors to the SHP2 inhibitor, migoprotafib, in combination with other targeted therapies. Finally, we showed that RIT1M90I can also drive resistance to the KRASG12C inhibitor, divarasib, and that the combination with migoprotafib can revert this phenotype. Our data shows that RIT1M90I is a bona fide oncogenic driver of NSCLC and mediator of targeted therapy resistance as a co-occurring mutation. Taken together, our study suggests that RIT1-altered cancer patients may benefit from combination treatment with SHP2 inhibitor in the primary and resistance setting. Citation Format: Ashley DiMarco, Mirunalini Ravichandran, Jeffery Lau, Anthony Lima, Eva Lin, Julie Weng, Luca Gerosa, Pablo Saenz-Lopez Larracho, Thomas Hunsaker, Yang Xiao, Monika Mis, Charles Havnar, Kai Barck, Klara Totpal, Oded Foreman, Mark Merchant, Nicole Sodir, Danilo maddalo. RIT1M90I is a driver of lung adenocarcinoma tumorigenesis and resistance to targeted therapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 6849.
Year:
2025
The KIAA1549-BRAF (KB) fusion is a prevalent genetic event in two distinct central nervous system tumors: pilocytic astrocytomas (PAs) and diffuse leptomeningeal glioneuronal tumors (DLGNTs). This chromosomal rearrangement, consisting of a 2 Mbp tandem duplication at 7q34, results in the formation of a fusion protein absent in normal cells. The KB fusion protein has been described to dimerize the BRAF kinase in a RAS-independent manner, leading to a constitutive activation of the MAPK pathway and promoting tumorigenesis. Despite its significance, the lack of pre-clinical models limits our understanding of how KB promotes DLGNTs and PAs development, so effective therapeutic strategies remain elusive. To address this, we aimed to model the KB fusion at its endogenous chromosomal location. Overcoming the challenges of modeling chromosomal rearrangements, we used the CRISPR-Cas9 gene-editing technique to model the fusion event ex vivo and in vivo in the mouse brain, leveraging p53- or Arf-deleted backgrounds. These models allow us to investigate the molecular mechanisms by which KB promotes tumor initiation and progression and test the therapeutic potential of Belvarafenib, a class II BRAF inhibitor that targets BRAF dimers. Our results demonstrate that CRISPR-mediated engineering of KB in p53- or Arf-deficient backgrounds, both ex vivo and in vivo, generates CNS tumors resembling human DLGNTs in their histology and growth patterns. Furthermore, targeting the robust MAPK pathway activation in these KB-driven tumor models with Belvarafenib significantly reduced ERK phosphorylation and tumor growth, and significantly increased the survival of treated mice. These findings demonstrate that KB promotes tumor initiation and progression, and highlight the therapeutic potential of Belvarafenib targeting this oncogenic event. Thus, our KB-DLGNTs model emerges as a valuable tool to evaluate the efficacy of novel pre-clinical BRAF inhibitors. Citation Format: Ylenia Cendon Florez, Ram Kannan, Matthias A. Karrajannis, Darlene Dela Cruz, Udi Segal, Danilo Maddalo, Scott Foster, Robert Benezra, Andrea Ventura. Unraveling Kiaa1549-Braf driven brain tumors: From modeling to therapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 7033.
Year:
2025
Supplemental Dataset 1 contains the difference in GR AOC values in the chemicogenomic screen for CRC cell lines HCT 116 (Supplemental Figure 4C), HCT-15, and T84 as well as Breast Cancer cell line MFM-223.
Year:
2025
PIK3CA and KRAS are among the most frequently mutated oncogenes and often co-mutated in colorectal cancers. Understanding the impact of KRAS codon–specific mutations on cross-talks between the PI3K and MAPK pathways and response to targeted therapies, such as the p110α-specific inhibitor inavolisib (GDC-0077), is critical for advancing precision oncology. Focusing on colorectal PIK3CA + KRAS co-mutated models, we found that KRAS G12D -mutated cells were more sensitive to inavolisib than models with KRAS G13D , or other MAPK pathway mutations, even though the PI3K and MAPK pathways were active in both genotypes. In most co-mutated models, regardless of the type of KRAS alteration, the combination of inavolisib with MAPK pathway inhibitors showed synergy in vitro and in vivo . Our work highlights how specific codon substitutions in KRAS differentially toggle pathway activity and alter sensitivity to inavolisib, which could inform whether patients would benefit more from single-agent inavolisib or combination with MAPK pathway inhibitors.
Year:
2025
Supplementary Figure S4: (A) NCI-H358-RIT1M90I cells are resistant to divarasib single agent treatment and can be re-sensitized with divarasib and migoprotafib combination both in vitro and in vivo.
Year:
2025
Supplementary Table S1: Assessment of immunohistochemistry staining intensity on lungs from RIT1 mice. Pathological findings are summarized for all tumors within each animal. Localization of CD3-positive T cells is described. IHC staining intensity is qualitatively scored as +++; strongly positive, +/-; mixed and description is included, -; negative.
Year:
2025
RIT1 is a RAS-family guanosine triphosphatase that is mutated in 2.4% and amplified in up to 14% of patients with lung adenocarcinoma. Yet the oncogenic potential of RIT1 in the lungs has not been fully established. Consequently, patients with RIT1 alterations are considered “oncogene-negative” and are not eligible for any targeted therapy in the clinic. The role of RIT1 in cancer has been historically understudied due to the lack of in vitro and in vivo models harboring RIT1 alterations. In this study, we generated a murine model of RIT1 M90I -mutant lung cancer. RIT1 M90I expression induced tumorigenesis in the lungs, and the tumors displayed histopathologic features similar to lung adenocarcinoma in humans. An unbiased chemical compound screen leveraging this model revealed a sensitivity to inhibitors of the MAPK, PI3K, and cholesterol biosynthesis pathways in RIT1-mutant cell lines. The SHP2 inhibitor, migoprotafib, in combination with other MAPK pathway–targeted therapies, effectively suppressed the growth of RIT1-mutant cells ex vivo and in vivo . Finally, RIT1 M90I drove resistance to the KRAS G12C inhibitor, divarasib, and the combination with migoprotafib reverted this phenotype. Together, these data show that RIT1 M90I is a bona fide oncogenic driver of lung cancer and a mediator of targeted therapy resistance as a co-occurring mutation and suggest that patients with RIT1-altered cancer may benefit from combination treatments with an SHP2 inhibitor. Significance: Development of a mouse model of RIT1 M90I -altered non-small cell lung cancer reveals that RIT1 M90I is a driver of lung tumorigenesis and that RIT1-mutated tumors are sensitive to MAPK pathway inhibitors. See related commentary by Wu and Vaishnavi, p. 3186 See related article by Mozzarelli et al., p. 3196
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Collaborators (15)
Melissa Ronan
Broad Institute
W. Patrick Walters
Relay Therapeutics Inc
Luca Gerosa
Senior Scientist
Genentech Inc
Roberto Chiarle
University of Turin
Nicole Jung
Karlsruhe Institute of Technology
Andrés Cervantes
Professor of Medicine
University of Valencia
Philippe L. Bedard
University Health Network
Molly Premtoon
Relay Therapeutics Inc
Kevin Kalinsky
Emory University
Peter Schmid
Professor of Cancer Medicine and Honorary Consultant in Medical Oncology, Centre Lead, Centre for Experimental Cancer Medicine
Barts Cancer Institute
Antoine Italiano
Université Paris-Saclay
Valentina Gambardella
INCLIVA Health Research Institute
Melissa K. Accordino
Columbia University
Cristina Saura Manich
Associate Professor
Universitat Autònoma de Barcelona (UAB)
Jennifer Roth
Broad Institute
Make your next move.
Prepare your application
Review drafts before you send them.